1.
|
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 85
Sponsor: Other
Protocol IDs: 20050113, NCT00243685
|
|
2.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: EFC10145, EudraCT 2007-003592-39, NCT00699517
|
|
3.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR003583, SAR-3002, ET743SAR3002, NCT00210665
|
|
4.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Under 30 at diagnosis
Sponsor: NCI
Protocol IDs: COG-ARST0332, ARST0332, NCT00346164
|
|
5.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 13 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AP23573-07-302, NCT00538239
|
|
6.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: DUMC-1308-04-7R5, DUMC-G040102, DUMC-G880018, NCT00093509
|
|
7.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: CHNMC-04090, NCT00233948
|
|
8.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: INST 0509C, NCT00276055
|
|
9.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 10 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A4021020, NCT00560235
|
|
10.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: NCI
Protocol IDs: UCCRC-16227A, 16227A, 8131, NCT00720174
|
|
11.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: TH-CR-403, NCT00742963
|
|
12.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20070411, NCT00819169
|
|
13.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 30 and under at diagnosis
Sponsor: NCI
Protocol IDs: MSKCC-03099, NCT00077285
|
|
14.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 10 and over
Sponsor: Other
Protocol IDs: UMCC 2004.010, NCT00189137
|
|
15.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NU-04S1, NCT00288015
|
|
16.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Any age
Sponsor: NCI
Protocol IDs: SARC-006, 006, NCI-06-C-0043, NCI-P6452, NCT00304083, UMN-2007CG077
|
|
17.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: MSKCC-05122, NCT00445965
|
|
18.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: NCI
Protocol IDs: CINJ-3330, NCT00161187
|
|
19.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 13
Sponsor: Other
Protocol IDs: SARC009, NCT00464620
|
|
20.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 10408, H8K-MC-JZAD, H8K-MC-JZAD(a), NCT00490451
|
|
21.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: REO 014, NCT00503295
|
|
22.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 18
Sponsor: NCI
Protocol IDs: NCI-07-C-0230, 07-C-0230, NCT00550654
|
|
23.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 13 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ARQ 197-204, NCT00557609
|
|
24.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 30 and under
Sponsor: NCI, Other
Protocol IDs: 05-326, NCT00592293
|
|
25.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA182-026, NCT00633789
|
